Report from the CVOT Summit 2020: new cardiovascular and renal outcomes

Abstract

The 6th Cardiovascular Outcome Trial (CVOT) Summit "Cardiovascular and Renal Outcomes 2020" was the first to be held virtually on October 29-30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA-CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed.The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18-19, 2021 ( http://www.cvot.org ).

Keywords: Cardiovascular disease; Chronic kidney disease; DAPA-CKD; Diabetes; EMPEROR-Reduced; FIDELIO-DKD; GLP-1 receptor agonist; Heart failure; Mineralocorticoid receptor antagonist; Obesity; SGLT2i inhibitor; VERTIS-CV.

Fig. 1

The living guideline model. Living systematic reviews that are constantly updated as new evidence becomes available produce trustworthy guidelines, which are also constantly updated as new evidence that changes direction or strength of recommendations be released (Adapted from: www.magicevidence.org/).